Murat BOZDAG

Dr. Murat BOZDAG

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2013 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MTMuhammet Tanc
Muhammet Tanc
FCFabrizio Carta
Fabrizio Carta
MBMurat BOZDAG
Murat BOZDAG
ASAndrea Scozzafava
Andrea Scozzafava
CSClaudiu T. Supuran
Claudiu T. Supuran

13 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMurat BOZDAG
Murat BOZDAG
MFMarta Ferraroni
Marta Ferraroni
FCFabrizio Carta
Fabrizio Carta
DVDaniela Vullo
Daniela Vullo
LLLaura Lucarini
Laura Lucarini
Claudiu SupuranClaudiu Supuran
Claudiu Supuran

1 January 2017 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MAMorteza Abdoli
Morteza Abdoli
AAAndrea Angeli
Andrea Angeli
MBMurat BOZDAG
Murat BOZDAG
FCFabrizio Carta
Fabrizio Carta
AKAli Kakanejadifard
Ali Kakanejadifard
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
A series of benzo[d]thiazole-5- and 6-sulfonamides has been synthesized and investigated for the inhibition of several human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms, using ethoxzolamide (EZA) as lead molecule. 2-Amino-substituted, 2-acylamino- and halogenated (bromo-and iodo-derivatives at the heterocyclic ring) compounds led to several interesting inhibitors against the cytosolic hCA I, II and VII, as well as the transmembrane, tumor-associated hCA IX isoforms. Several subnanomolar/low nanomolar, isoform-selective sulfonamide inhibitors targeting hCA II, VII and IX were detected. The sharp structure–activity relationship for CA inhibition with this small series of derivatives, with important changes of activity observed even after minor changes in the scaffold or at the 2-amino moiety, make this class of scarcely investigated sulfonamides of particular interest for further investigations.

Verified
Journal Article
Open access
PDF file
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
VKVisvaldas Kairys
Visvaldas Kairys
SRSangeetha Rala
Sangeetha Rala
MPMataleena Parikka
Mataleena Parikka
MBMurat BOZDAG
Murat BOZDAG
SPSeppo Parkkila
Seppo Parkkila
The genome of Mycobacterium tuberculosis (Mtb) encodes three β-carbonic anhydrases (CAs, EC 4.2.1.1) that are crucial for the life cycle of the bacterium. The Mtb β-CAs have been cloned and characterized, and the catalytic activities of the enzymes have been studied. The crystal structures of two of the enzymes have been resolved. In vitro inhibition studies have been conducted using different classes of carbonic anhydrase inhibitors (CAIs). In vivo inhibition studies of pathogenic bacteria containing β-CAs showed that β-CA inhibitors effectively inhibited the growth of pathogenic bacteria. The in vitro and in vivo studies clearly demonstrated that β-CAs of not only mycobacterial species, but also other pathogenic bacteria, can be targeted for developing novel antimycobacterial agents for treating tuberculosis and other microbial infections that are resistant to existing drugs. In this review, we present the molecular and structural data on three β-CAs of Mtb that will give us better insights into the roles of these enzymes in pathogenic bacterial species. We also present data from both in vitro inhibition studies using different classes of chemical compounds and in vivo inhibition studies focusing on M. marinum, a model organism and close relative of Mtb.

30 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MBMurat BOZDAG
Murat BOZDAG
MPMelissa Pinard
Melissa Pinard
FCFabrizio Carta
Fabrizio Carta
EMEmanuela Masini
Emanuela Masini
ASAndrea Scozzafava
Andrea Scozzafava
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
We report a series of 4-sulfamoylphenyl-ω-aminoalkyl ethers as carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. The structure–activity relationship was drawn for the inhibition of four physiologically relevant isoforms: hCA I, II, IX, and XII. Many of these compounds were highly effective, low nanomolar inhibitors of all CA isoforms, whereas several isoform-selective were also identified. X-ray crystal structures of two new sulfonamides bound to the physiologically dominant CA II isoform showed the tails of these derivatives bound within the hydrophobic half of the enzyme active site through van der Waals contacts with Val135, Leu198, Leu204, Trp209, Pro201, and Pro202 amino acids. One of the highly water-soluble compound (as trifluoroacetate salt) showed effective IOP lowering properties in an animal model of glaucoma. Several fluorescent sulfonamides incorporating either the fluorescein-thiourea (7a–c) or tetramethylrhodamine-thiourea (9a,b) moieties were also obtained and showed interesting CA inhibitory properties for the tumor-associated isoforms CA IX and XII.